###### Abstract
\begin{table}
\begin{tabular}{c c c c c c c c} \hline \hline
**Polymeric** & **Arns 1\({}^{,}\)2** & **Architecture** & **Stimulus** & **Cargo** & \begin{tabular}{c} **Encapsulation** \\ **Efficiency (\%)** \\ \end{tabular} & \
\begin{tabular}{c} **Loading** \\ **Capacity (\%)** \\ \end{tabular} & **Year** & **Citation** \\ \hline PNIPAM, PUA & AB\({}_{2}\) & Temperature & Prednisone acetate & 27.7 & N/A & 2006, 2009, & [27] \\ PEG, PCL, P2 VP & ABC & pH & Nile Red & N/A & N/A & 2012 & [28; 29; 30] \\ PMMA, & AB\({}_{3}\) & Temperature & Prednisone acetate & 55 & N/A & 2007 & [31] \\ PNIPAM & AB\({}_{2}\) & Indomethacina & 27.3–56.6 & 9.1–21.4 & 2008 & [32] \\ PEG, PCL & A\({}_{2}\)B\({}_{2}\) & Ibuprofen & 26.8–89.7 & 7.3–20.3 & 2009 & [33] \\ PEG, PLLA & AB\({}_{2}\) & Doxorubicin & 72 & N/A & 2009 & [34] \\ PEG, PLLA & ABC, AB\({}_{2}\) & Paclitaxel & N/A & 5.0–11.6 & 2009 & [35] \\ PCL, PEG & A\({}_{14}\)B\({}_{7}\) & Ibuprofen & 7.7–46.0 & 2.3–13.8 & 2010 & [36] \\ PEG, PCL & A\({}_{2}\)B & Nimodipine & 23–70 & 2.3–7.0 & 2010 & [24] \\ PEG, PCL & AB\({}_{10}\) & Prednisone acetate & 21.1–4.5 & 2.1–4.3 & 2010 & [37] \\ PNIPAM, PLL & AB\({}_{2}\) & Prednisone acetate & 18.6–21.4 & 2.1–2.5 & 2010 & [38] \\ PEG, PS, PCL & ABC & Disperse Red 1 & N/A & 0.4–21 & 2010 & [39] \\ PEG, PCL & AB\({}_{2}\), A(B)A\({}_{2}\) & Rhodamine B & 40–57 & N/A & 2011 & [40] \\ PEG, Niacin, & & isothiocyanate-Dextran & & & & \\ PEG, NaCl, & A\({}_{2}\)B, ABC & & Nacin & N/A & N/A & 2011 & [41] \\ PEG, PCL, & ABC & & Coenzyme Q10 & 83–85 & 8.3–8.5 & 2012 & [42] \\ TPPF & & & & & & 0.92–1.42 & 2012, 2014 & [43; 44] \\ PEG, PHis & AB\({}_{2}\) & pH & 5(6)-carboxogluc fluorescein & N/A & \(\mu\)L mg\({}^{-1}\) & 2012, 2014 & [43; 44] \\ PCL, PEG, PLL & ABC & & DNA & N/A & 5.0 & 2013 & [45] \\ PAzo, PDEAA & AB\({}_{3}\) &
\begin{tabular}{c} UV light, \\ Temperature \\ \end{tabular} & Nile Red & N/A & N/A & 2013 & [46] \\ PEG, PCL & AB\({}_{2}\) & Curcumin & 48.5–65.0 & 4.6–6.5 & 2014 & [47] \\ PCL, PBLA, & ABC & & Doxorubicin & 56.2 & 11.2 & 2014 & [48] \\ PEG, PCL, TTF & ABC & & Curcumin & 39.2–55.9 & 3.9–5.6 & 2014 & [49] \\ PCL, & & & & & & \\ PDEAEMA-b- & A\({}_{2}\)(BC)\({}_{2}\) & pH & Doxorubicin & N/A & 10 & 2014 & [50] \\ PEGMA & & & & & & \\ PEG, PGA & & & & & & \\ PEG, PGA & AB\({}_{2}\) & pH & Doxorubicin & 29.4–71.4 & 9.5–19.6 & 2014 & [51] \\ PZao, PEG & AB\({}_{3}\) & UV light & & Noe Red, & N/A & 16.2–18.2 & 2014 & [52] \\ PEG, PCL & AB\({}_{2}\) & & Nile Red, & N/A & N/A & 2014 & [53] \\ PCL, PEG & AB\({}_{2}\) & & Doxorubicin & 41.6–72.7 & 6.1–16.1 & 2015 & [54] \\ PCL, PEG & & & Curcumin & 17.3–27.6 & 11.4–13.3 & 2015 & [55] \\ PEG, PAA, PCL & ABC & pH & Naproven & 58.2–72.8 & 9.7–12.1 & 2015 & [56] \\ PEG, PEG-b- & A\({}_{2}\)(AB)\({}_{2}\) & Redox & Camptothecin & N/A & 3.6–10.8 & 2015 & [57] \\ PCL, P\({}_{\text{A}}\)(AB)\({}_{2}\) & Redox & Methorexateate & 64 & 16 & 2015 & [58] \\ PCL, PCL-b- & & & & Doxorubicin & 52.8–54.6 & 8.8–9.1 & 2016 & [59] \\ PEG & & & & Doxorubicin & 24.7 & 5.6 & 2016 & [60] \\ PEG, PPLG & A\({}_{16}\)B\({}_{23}\) CCS & & siRNA & N/A & N/A & 2016 & [61] \\ PEG, & & & & & & \\ P(MMA-co- \\ MAA) & & & & & & & & \\ PCL, P(MAA-co- \\ MMA) & & & & & & & \\ PEG, & & & & & & \\ qPDMAMEMA & & & & & & \\ PPEGMA, & & & & & & \\ PMMA, & (BA)(AC)\({}_{2}\) & Temperature & Celecoxib & N/A & 8.8 & 2016 & [65] \\ PNIPAM & & & & & & & \\ PEC, PNBM, & & UV light, & & & & \\ PNIPAM & ABC & Temperature & Nile Red & N/A & N/A & 2017 & [66] \\ PEG, PGA & AB\({}_{3}\) & Lysozyme & N/A & N/A & 2017, 2018 & [67; 68] \\ PVDF, PS, PEG & (AB)\({}_{2}\)C\({}_{2}\) & & Nile Red & N/A & N/A & 2018 & [69] \\ PCL, POGEMMA & A\({}_{2}\)B, A\({}_{2}\)B\({}_{2}\) & & & & & \\ AB\({}_{3}\), A\({}_{3}\)B & & Doxorubicin & 34.3–62.9 & 4.4–8.1 & 2018 & [70] \\ \hline \hline \end{tabular}
\end{table} 
Table 1: Miktoarm star polymers in drug delivery.